By ‘decorating’ nanosized liposomes encapsulating VCR, a first-line chemotherapeutic for RMS, we aim to improve the efficacy of existing chemotherapies and minimize long-lasting side effects. We will characterize the leakiness of the vasculature in different RMS xenografts, to assess the characteristics and impact the EPR effect can have in our system. The pharmaceutical properties of liposomes targeted to RMS with peptides or nanobodies, and of control liposomes will be characterized both in vitro and in vivo. In particular we will compare the therapeutic efficacy of our novel formulations with that of the clinically approved VCR formulation Marqibo. The biodistribution and antitumoral activity of the drug loaded liposomal formulations will be investigated in a preclinical model of alveolar and embryonal RMS.